Latest News and Press Releases

BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human,...

Company Announcement Net sales of DARZALEX® in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity...

STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...

Company announcement no. 10 - 2614 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Asgard Therapeutics announces the appointment of experienced medical oncologist, Professor Dr. Wolfram Brugger, as Chief Medical Officer.

PannTheraPi files Phase 2a trial for epilepsy drug PTI5803, secures EU patent, and appoints Sophie Binay as GM & CSO.

IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today...

WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody...

PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to...

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)